Coiled Therapeutics Reports Encouraging AO-252 Trial Data and Moves Toward Dose Expansion

Coiled Therapeutics (LSE:COIL) has released promising interim results from its ongoing Phase I/II clinical trial evaluating AO-252. The study reported an 80% clinical benefit rate, with patients in the twice-daily dosing cohort experiencing disease control lasting more than six months. This outcome compares favourably with the once-daily dosing arm and with typical results from salvage therapies used in heavily pre-treated solid tumour patients.

The treatment has so far demonstrated a favourable safety profile, with no maximum tolerated dose reached during the study. Researchers have also observed signs of immune-modulating activity involving the cGAS/STING pathway, which may enhance the therapy’s anti-cancer potential. Based on these findings, the company plans to move quickly into dose expansion studies targeting ovarian and prostate cancers. Additional development steps include introducing a next-generation formulation of the drug and launching combination therapy studies in 2026, potentially strengthening AO-252’s clinical prospects and future commercial positioning.

Despite the encouraging clinical progress, the company’s investment outlook remains constrained by weak financial fundamentals. Coiled continues to report volatile pre-commercial revenue, ongoing losses and persistent cash burn. Technical indicators also reflect a prolonged downward trend in the share price. While the balance sheet carries relatively low leverage, the stock’s negative price-to-earnings ratio and absence of dividend yield limit its valuation appeal.

More about Coiled Therapeutics plc

Coiled Therapeutics plc is an AIM-listed clinical-stage biotechnology company developing precision oncology therapies for difficult-to-treat solid tumours. Its lead programme, AO-252, is a first-in-class orally administered TACC3 inhibitor currently undergoing Phase I trials in the United States. The company is also advancing a STAT-6 siRNA programme aimed at immunology indications and benefits from strategic support from A2A Pharmaceuticals.